Day: January 19, 2026

                                                 Press release Lesquin, January 19, 2026,6:00 PM SALES FOR THE FIRST 9 MONTHS OF FISCAL YEAR 2025-26 AT €219.8 M BIGBEN INTERACTIVE (ISIN FR 0000074072) today announced its consolidated sales for the first nine months of the fiscal year 2025-26 (period from April 1, 2025 to December 31, 2025).IFRS – €M 2025/262024/25% ChangeSales1 st Quarter (April – June) 56,5 57,9 -2.4%       2 nd Quarter (July – Sept. ) 79,0 78,0 +1.3%       3 rd Quarter (Oct. – Dec. ) (1) 84,4 87,7 -3.8%Nacon Gaming 46,1 52,9 -12.8%Bigben Audio-vidéo / Telco 38,2 34,8 +9.9%       Cumulative 9 months (April – December) (1) 219,8 223,6 -1.7%       Nacon Gaming 124,2 129,9 -4.4%Bigben Audio-vidéo / Telco 95,6 93,7 +2.1%       (1)   Unaudited data Sales for...

2026 financial communication calendar Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, releases its 2026 financial communication calendarDate EventJanuary 28, 2026 Q4 2025 turnover (after market close)March 12, 2026 2025 full-year results (before market open)April 23, 2026 Q1 2026 turnover (after market close)May 21, 2026 Annual General MeetingJuly 23, 2026 Q2 2026 turnover (after market close)September 03, 2026 2026 half-year results (before market open)0ctober 22, 2026 Q3 2026 turnover (after market close)Next on the agenda: Q4 2025 turnover, January 28, 2026 (after market close)About Voltalia (www.voltalia.com)Voltalia is an international player in renewable energies. The Group produces and sells electricity from its wind, solar, hydro, biomass and storage...

Press release – Neuilly-sur-Seine, Monday, January 19, 2026 – 6.30 pm Ms. Laurence BATLLE joins ARGAN’s Supervisory Board At the meeting of the Supervisory Board held on December 9, 2025, and as a result of the signing of an employment contract between the Company and Mr. Eric DONNET effective from January 2, 2026, it was acknowledged that Mr. Eric DONNET no longer met all of the independence criteria set out in the Middlenext corporate governance code to which the Company refers, and therefore ceased to be considered independent within the meaning of said code. In light of this situation, Mr. Jean-Claude LE LAN Junior informed the members of the Supervisory Board of his intention to resign, with effect from December 31, 2025, in order to allow the Company to adjust its governance in compliance with the required quota of independent members. On...

                                                Press Release Lesquin, January 19, 2026 – 6:00 p. m. SALES FOR THE FIRST 9 MONTHS OF FISCAL YEAR 2025-26 AT €124.2 M NACON (ISIN FR0013482791) has today reported its consolidated sales for the first nine months of the 2025/26 financial year (nine months from 1 April 2025 to 31 December 2025).IFRS – M€ 2025-262024-25ChangeSales1 st Quarter (April-June) 31.3 32.3 -2.9%       2 nd Quarter (Jul. -Sept. ) 46.8 44.8 +4.5%       3 rd Quarter (Oct. – Dec. ) 46.1 52.9 -12.8%Games 25.9 25.4 +1.9%Of which: Catalogue 13.7 9.8 +39.9%Back catalogue 12.2 15.6 -21.8%Accessories 17.9 25.2 -29.1%Other (1) 2.4 2.3 +4.6%       Cumulative 9 months (April-Dec. ) 124.2 129.9 -4.4%       Games 82.3 71.1 +15.7%Of which: Catalogue 42.1 28.5 +47.4%Back...

Company voluntarily withdraws IXCHIQ BLA and IND in the U.S.  Continuing review of global product opportunity according to medical need and commercial attractivenessSaint Herblain (France), January 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ®, in the United States, following suspension of the license by the U.S. Food and Drug Administration (FDA) in August 2025. The Company had been awaiting further information with respect to its formal response to the vaccine license suspension. Valneva was recently informed of the FDA’s further decision to now place the Investigational New Drug (IND) on clinical hold...

 PRESS RELEASE Arcueil, January 19, 2026 Declaration of transactions on own shares conducted from January 12 to January 16, 2026 Within the framework of the authorizations granted by the General Assembly on February 4, 2025, to operate on its shares and in accordance with the regulations related to share buybacks, Aramis Group hereby declares the following purchases of own shares (FR0014003U94) made from January 12 to January 16, 2026 (excluding the liquidity contract):Name of the issuer Issuer identifier code Transaction date Financial instrument identifier code Total daily volume (in number of shares) Daily weighted average purchase price of shares MarketAramis Group 9695002Q984W0T41WB42 2026-01-12 FR0014003U94 1,035 4.8279 XPARAramis Group 9695002Q984W0T41WB42 2026-01-13 FR0014003U94 2,120 4.7166 XPARAramis Group 9695002Q984W0T41WB42 2026-01-14 FR0014003U94 2,131 4.6906 XPARAramis...

Regulated information Paris, January 19, 2026 DISCLOSURE FISCAL 2026/11 OF TRANSACTIONS ON TREASURY SHARES  Period of: January 12 to January 16, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49)  Aggregate presentation by day and by market.Issuer Code Transaction date ISIN Code Daily total volume (in number of shares) Daily weighted average price of shares acquired Platform213800RQNIQT48SEEO85 12-Jan-26 NL0015001W49 38 050 12,4396 XPAR213800RQNIQT48SEEO85 12-Jan-26 NL0015001W49 25 700 12,4174 DXE213800RQNIQT48SEEO85 12-Jan-26 NL0015001W49 3 950 12,4378 TQE213800RQNIQT48SEEO85 13-Jan-26 NL0015001W49 44 850 12,1073 XPAR213800RQNIQT48SEEO85 13-Jan-26 NL0015001W49 26 250 12,1664 DXE213800RQNIQT48SEEO85 13-Jan-26 NL0015001W49 3 900 12,2640 TQE213800RQNIQT48SEEO85 14-Jan-26 NL0015001W49 45...

Paris, 19 January 2026 Full-year results and Q4 2025 sales: 25 March 2026*Quiet period: from 11 to 25 March 2026Q1 2026 sales: 21 May 2026*Quiet period: from 7 May to 21 May 2026Annual General Meeting: 18 June 2026 Half-year results and Q2 2026 sales: 23 September 2026*Quiet period: from 9 to 23 September 2026Q3 2026 sales: 1 December 2026*Quiet period: from 17 November to 1 December 2026* Publication after market close About Quadient® Quadient is a global automation platform powering secure and sustainable business connections through digital and physical channels. Quadient supports businesses of all sizes in their digital transformation and growth journey, unlocking operational efficiency and creating meaningful customer experiences. Listed in compartment B of Euronext Paris (QDT) and part of the CAC Mid & Small...

Aspo Plc  ANNOUNCEMENT  19.1.2026          Aspo Plc: Share repurchase 19.1.2026       In the Helsinki Stock Exchange         Trade date           19.1.2026  Bourse trade         Buy  Share                  ASPO  Amount             1 000 SharesAverage price/ share    7,1980 EURTotal cost            7 198,00 EUR          Aspo Plc now holds a total of 121 552 shares  including the shares repurchased on 19.1.2026       The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5and the Commission Delegated Regulation (EU) 2016/1052.          On behalf of Aspo Plc         Nordea Bank Oyj              Sami Huttunen Ilari Isomäki       For more information, please contact:  Erkka Repo,...